lurasidone - Page 1 | CARLAT PUBLISHING

Research Update

Lurasidone vs Quetiapine in Bipolar Depression

September 1, 2023

Kate Travis, MD. Dr. Travis has no financial relationships with companies related to this material.

Both these medications work in bipolar depression, but this analysis compared them head-to-head for a different primary outcome: Cognition in bipolar disorder.

Bipolar Upgrade 3: Lurasidone

August 7, 2023

Chris Aiken, MD. and Kellie Newsome, PMHNP

Lurasidone (Latuda) has gone generic. Find out where this antipsychotic fits in bipolar disorder with updates from the 2023 International Bipolar Conference.

Clinical Update

Treating Irritability in Autism: Functional and Medication Approaches

April 1, 2023

Joshua Feder, MD

Joshua D. Feder, MD. Editor-in-Chief, The Carlat Child Psychiatry Report.

Dr. Feder has no financial relationships with companies related to this material.

Antipsychotics can be very effective for irritability in autism, but they are often unnecessary, and the side effects are truly problematic. Don’t be the prescriber who hears irritability in autism and immediate prescribes antipsychotics. There are usually multiple steps to try before using the FDA approved antipsychotic medications.

Medication Management of Antipsychotic-Induced Weight Gain in Children and Teens

July 25, 2022

Joshua Feder, MD and Mara Goverman

Second-generation antipsychotics routinely breach the FDA’s level of concern of >7% body weight gain. This article examines the efficacy and safety of using off-label medications, such as metformin, to manage this side effect.

Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia

November 5, 2021

Garrett Rossi, MD.

Garrett Rossi, MD. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Study suggests we may be underdosing this antipsychotic in schizophrenia.

Pharmacotherapy for Autism Spectrum Disorder

May 20, 2021

Matthew Krause, DO

Matthew Krause, DO

Child psychiatrist with Primary Health Network, Latrobe, PA Dr. Krause has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What’s new in psychopharmacological treatment for autism? We interviewed Dr. Matthew Krause on his recent review of seven studies covering the rationale for treatment, target symptoms, the use of antipsychotics, over the counter supplements, and some new ideas in pharmacotherapy for ASD.

Mood Stabilizers: What You Don’t Know Can Hurt Them

October 6, 2020

Nicholas Rosenlicht, MD.

Nicholas Rosenlicht, MD. Dr. Rosenlicht has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are many mood stabilizers to choose from, but which ones are the best tolerated? This meta-analysis looks at how they stack up in terms of weight gain, sedation, and overall discontinuation.